CA
SRNE

Clearstead Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Clearstead Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-130
Closed -$115 – 1452
2022
Q4 		$115 Hold
130
– – ﹤0.01% 1284
2022
Q3 		$0 Hold
130
– – ﹤0.01% 1399
2022
Q2 		$0 Hold
130
– – ﹤0.01% 1499
2022
Q1 		$0 Hold
130
– – ﹤0.01% 1480
2021
Q4 		$1K Hold
130
– – ﹤0.01% 1245
2021
Q3 		$1K Hold
130
– – ﹤0.01% 1266
2021
Q2 		$1K Hold
130
– – ﹤0.01% 1230
2021
Q1 		$1K Hold
130
– – ﹤0.01% 1098
2020
Q4 		$1K Buy
+130
New +$1.04K ﹤0.01% 972

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

Clearstead Advisors's SRNE Position: Q1 2023 in Review

Clearstead Advisors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 130 shares — an estimated $115 sold.

Clearstead Advisors first reported a position in SRNE in Q4 2020 and held it in 9 quarters. The position peaked at $1K in Q4 2021. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • Clearstead Advisors reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Clearstead Advisors sold 130 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $115.
  • Clearstead Advisors first reported a position in Sorrento Therapeutics, Inc. in Q4 2020 and held it in 9 quarters.
  • Clearstead Advisors's Sorrento Therapeutics, Inc. position peaked at $1K in Q4 2021.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Clearstead Advisors's 13F filing for Q1 2023, filed 9 May 2023.